Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317387864> ?p ?o ?g. }
- W4317387864 abstract "Background Immunotherapy has improved the clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC). However, in patients with Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutations, the superior efficacy of immunotherapy has not been elucidated and especially in real-world practice. Our study aimed to use real-world data to assess the efficacy of immunotherapy in KRAS -mutant NSCLC in a Chinese cohort. Methods In this retrospective cohort study, we extracted the clinical, molecular, and pathologic data from the electronic health records of patients with advanced KRAS -mutant NSCLC at Shandong Cancer Hospital between January 2018 and May 2022. Furthermore, we evaluated the progression-free survival (PFS) and overall survival (OS) of the included patients. Results Between January 2018 and November 2020, 793 patients were identified with stage IIIB-IV NSCLC and a total of 122 patients with KRAS mutations were included in the analysis. The majority of patients were diagnosed with stage IV (82.0%) adenocarcinoma (93.4%), along with a history of smoking (57.4%). Of these, 42% of patients received anti-PD-(L)1 with or without chemotherapy (Immunotherapy-based regimens), while 58.2% of patients received chemotherapy (Chemotherapy-based regimens). The median overall survival (mOS) in this cohort was 22.9 months (95% CI: 14.1–31.7), while the median-progression-free survival (mPFS) was 9.4 months (95% CI: 6.6–12.1). Patients receiving immunotherapy-based regimens displayed better mOS than those receiving chemotherapy-based regimens (45.2 vs. 11.3 months; P =1.81E-05), with no statistical difference observed in the mPFS (10.5 vs. 8.2 months; P =0.706). Patients receiving immunotherapy-based regimens either in the first line ( P =0.00038, P =0.010, respectively) or second-line setting ( P =0.010, P =0.026, respectively) showed benefits in both PFS and OS. Subgroup analysis indicated that in patients having KRAS G12C or non- KRAS G12C mutant types, immunotherapy showed benefits of better OS ( P =0.0037, P =0.020, respectively) than chemotherapy. Moreover, in advanced NSCLCs patients with or without KRAS/TP53 co-mutation the immunotherapy-based regimen achieved longer OS and PFS than chemotherapy-based regimens. Conclusions In the Chinese population of patients with KRAS -mutant advanced NSCLC, immunotherapy-based regimens achieved longer OS than chemotherapy-based regimens, which was independent of first or second-line setting, as well as KRAS mutational subtypes." @default.
- W4317387864 created "2023-01-19" @default.
- W4317387864 creator A5005260985 @default.
- W4317387864 creator A5037754427 @default.
- W4317387864 creator A5039632100 @default.
- W4317387864 creator A5047320009 @default.
- W4317387864 creator A5054316895 @default.
- W4317387864 creator A5055401170 @default.
- W4317387864 creator A5056540688 @default.
- W4317387864 creator A5063591793 @default.
- W4317387864 creator A5070095637 @default.
- W4317387864 creator A5078857527 @default.
- W4317387864 creator A5081635779 @default.
- W4317387864 creator A5084928091 @default.
- W4317387864 date "2023-01-19" @default.
- W4317387864 modified "2023-10-03" @default.
- W4317387864 title "Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population" @default.
- W4317387864 cites W2129590156 @default.
- W4317387864 cites W2561459036 @default.
- W4317387864 cites W2609015711 @default.
- W4317387864 cites W2611896937 @default.
- W4317387864 cites W2772899582 @default.
- W4317387864 cites W2783760762 @default.
- W4317387864 cites W2804050059 @default.
- W4317387864 cites W2804812017 @default.
- W4317387864 cites W2808822836 @default.
- W4317387864 cites W2898735291 @default.
- W4317387864 cites W2906754611 @default.
- W4317387864 cites W2911842472 @default.
- W4317387864 cites W2913235593 @default.
- W4317387864 cites W2946827583 @default.
- W4317387864 cites W2981114563 @default.
- W4317387864 cites W2982321167 @default.
- W4317387864 cites W2985245838 @default.
- W4317387864 cites W2995281612 @default.
- W4317387864 cites W2996343037 @default.
- W4317387864 cites W2996463763 @default.
- W4317387864 cites W2997880339 @default.
- W4317387864 cites W3010178462 @default.
- W4317387864 cites W3022512725 @default.
- W4317387864 cites W3035177263 @default.
- W4317387864 cites W3111859532 @default.
- W4317387864 cites W3126239108 @default.
- W4317387864 cites W3128646645 @default.
- W4317387864 cites W3151969205 @default.
- W4317387864 cites W3171675220 @default.
- W4317387864 cites W3172081492 @default.
- W4317387864 cites W3190297823 @default.
- W4317387864 cites W3192028440 @default.
- W4317387864 cites W4213133214 @default.
- W4317387864 cites W4224305911 @default.
- W4317387864 cites W4282037505 @default.
- W4317387864 doi "https://doi.org/10.3389/fonc.2022.1070761" @default.
- W4317387864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36741723" @default.
- W4317387864 hasPublicationYear "2023" @default.
- W4317387864 type Work @default.
- W4317387864 citedByCount "2" @default.
- W4317387864 countsByYear W43173878642023 @default.
- W4317387864 crossrefType "journal-article" @default.
- W4317387864 hasAuthorship W4317387864A5005260985 @default.
- W4317387864 hasAuthorship W4317387864A5037754427 @default.
- W4317387864 hasAuthorship W4317387864A5039632100 @default.
- W4317387864 hasAuthorship W4317387864A5047320009 @default.
- W4317387864 hasAuthorship W4317387864A5054316895 @default.
- W4317387864 hasAuthorship W4317387864A5055401170 @default.
- W4317387864 hasAuthorship W4317387864A5056540688 @default.
- W4317387864 hasAuthorship W4317387864A5063591793 @default.
- W4317387864 hasAuthorship W4317387864A5070095637 @default.
- W4317387864 hasAuthorship W4317387864A5078857527 @default.
- W4317387864 hasAuthorship W4317387864A5081635779 @default.
- W4317387864 hasAuthorship W4317387864A5084928091 @default.
- W4317387864 hasBestOaLocation W43173878641 @default.
- W4317387864 hasConcept C121608353 @default.
- W4317387864 hasConcept C126322002 @default.
- W4317387864 hasConcept C143998085 @default.
- W4317387864 hasConcept C146357865 @default.
- W4317387864 hasConcept C151730666 @default.
- W4317387864 hasConcept C167135981 @default.
- W4317387864 hasConcept C2776256026 @default.
- W4317387864 hasConcept C2776694085 @default.
- W4317387864 hasConcept C2777701055 @default.
- W4317387864 hasConcept C2781182431 @default.
- W4317387864 hasConcept C2781187634 @default.
- W4317387864 hasConcept C2908647359 @default.
- W4317387864 hasConcept C526805850 @default.
- W4317387864 hasConcept C71924100 @default.
- W4317387864 hasConcept C72563966 @default.
- W4317387864 hasConcept C86803240 @default.
- W4317387864 hasConcept C99454951 @default.
- W4317387864 hasConceptScore W4317387864C121608353 @default.
- W4317387864 hasConceptScore W4317387864C126322002 @default.
- W4317387864 hasConceptScore W4317387864C143998085 @default.
- W4317387864 hasConceptScore W4317387864C146357865 @default.
- W4317387864 hasConceptScore W4317387864C151730666 @default.
- W4317387864 hasConceptScore W4317387864C167135981 @default.
- W4317387864 hasConceptScore W4317387864C2776256026 @default.
- W4317387864 hasConceptScore W4317387864C2776694085 @default.
- W4317387864 hasConceptScore W4317387864C2777701055 @default.
- W4317387864 hasConceptScore W4317387864C2781182431 @default.
- W4317387864 hasConceptScore W4317387864C2781187634 @default.